Organigram Product Development Collaboration Completes Landmark Clinical Study on Nanoemulsion Technology
August 07 2024 - 6:00AM
Business Wire
FAST™ Nanoemulsion Technology Expected to be
a Competitive Advantage for Organigram’s Ingestible
Portfolio
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), a leading
licensed producer of cannabis, is pleased to unveil the preliminary
results of its landmark clinical pharmacokinetic (PK) study
conducted via the Product Development Collaboration (PDC) on its
latest innovation, nanoemulsion technology. This patent-pending
technology, branded FAST™ (Fast Acting Soluble
Technology), will be the first innovation to be commercialized
by Organigram leveraging the output of the PDC*, a “Center of
Excellence” established to focus on developing next-generation
cannabis products.
The clinical study was completed in January 2024, and the final
data set has been received and reviewed. The final report is
expected to be published in October 2024.
The results of the study have given early indications of
technological advances, including but not limited to:
- Faster onset compared to traditional ingestible products from
the control group. Depending on ingestible format, up to
approximately 50% faster onset of the effects of cannabis was
observed.
- Improved bioavailability of cannabinoids: up to double the
cannabinoid delivery at peak compared to the control group.
- Early indicators of a more predictable duration of the effects
of cannabis showing promising signals for the development of future
offset claims, subject to additional supporting studies.
“We are thrilled with the study findings. The patent-pending
nanoemulsion technology, FAST™, promises to unlock the power of the
ingested cannabinoids and allow consumers to navigate and control
their dosage experience more accurately – a key consumer pain point
in the ingestible product space. These technological advances
underscore Organigram’s commitment to consumers and to developing
science-driven innovations” said Borna Zlamalik, SVP of Innovation
and R&D.
Organigram has analyzed and intends to leverage the data to
substantiate functional technology claims, adhering to Health
Canada regulations. "As a responsible licensed producer, our aim is
to thoroughly educate consumers about the effects of this
technology, empowering them to enjoy a controlled and predictable
ingestible experience,” added Mr. Zlamalik.
The study is believed to be one of the largest PK studies
targeted at adult-use recreational cannabis products. The robust,
19-day in-clinic, eight-arm study executed by a leading third-party
clinical research organization evaluated cannabinoid absorption
across three key product formats to determine the effectiveness of
the innovative delivery system.
Organigram expects to commercialize FAST™ in the fall of 2024,
beginning with gummies. Manufacturing scale-up trials for these
gummies are currently underway at Organigram’s Winnipeg
facility.
“Organigram has always been focused on consumer-centric
innovation as one of its core differentiators and our commitment to
the development of advanced technologies underscores this
commitment,” said Beena Goldenberg, CEO of Organigram. “We are
confident that our investment in this technology will pave the way
for our continued success in the edibles space both here and in
future abroad.”
*The Product Development Collaboration (“PDC”) is a joint
collaboration between BAT and Organigram and was established to
focus on developing next-generation cannabis products.
About Organigram
Organigram is a NASDAQ Global Select Market and TSX listed
company whose wholly owned subsidiary Organigram Inc. is a licensed
producer of cannabis, cannabis-derived products and
cannabis-infused edibles in Canada.
Organigram is focused on producing high-quality, cannabis for
adult recreational consumers as well as developing international
business partnerships to extend the Company’s global footprint.
Organigram has also developed and acquired a portfolio of legal
adult-use recreational cannabis brands, including Edison, Holy
Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian,
Tremblant Cannabis and Trailblazer. Organigram operates cultivation
and manufacturing facilities in Moncton, New Brunswick and
Lac-Supérieur, Quebec, with a dedicated edibles manufacturing
facility in Winnipeg, Manitoba. The Company is regulated by Health
Canada under the Cannabis Act and the Cannabis Regulations
(Canada).
Forward-Looking Information
This news release contains forward-looking information. Often,
but not always, forward-looking information can be identified by
the use of words such as “plans”, “expects”, “estimates”,
“intends”, “anticipates”, “believes” or variations of such words
and phrases or state that certain actions, events, or results
“may”, “could”, “would”, “might” or “will” be taken, occur or be
achieved. Forward-looking information involves known and unknown
risks, uncertainties and other factors that may cause actual
results, events, performance or achievements of Organigram to
differ materially from current expectations or future results,
performance or achievements expressed or implied by the
forward-looking information contained in this news release.
Risks, uncertainties and other factors involved with
forward-looking information could cause actual events, results,
performance, prospects and opportunities to differ materially from
those expressed or implied by such forward-looking information
include factors and risks such as regulatory and market conditions,
the outcome of commercialization efforts together with those
factors and risks disclosed in the Company’s most recent annual
information form, management’s discussion and analysis and other
Company documents filed from time to time on SEDAR+ (see
www.sedarplus.ca) and filed or furnished to the Securities and
Exchange Commission on EDGAR (see www.sec.gov). Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press
release.
Although the Company believes that the assumptions and factors
used in preparing the forward-looking information in this news
release are reasonable, undue reliance should not be placed on such
information and no assurance can be given that such events will
occur in the disclosed time frames or at all. The forward-looking
information included in this news release are made as of the date
of this news release and the Company disclaims any intention or
obligation, except to the extent required by law, to update or
revise any forward-looking information, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240807039495/en/
For Media enquiries: Megan McCrae Senior Vice President
of Global Brands and Corporate Affairs megan.mccrae@organigram.ca
For Investor Relations enquiries: Max Schwartz Director of
Investor Relations investors@organigram.ca
Organigram (NASDAQ:OGI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Organigram (NASDAQ:OGI)
Historical Stock Chart
From Oct 2023 to Oct 2024